Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Bartlett JMS, Xu K, Wong J, Pond G, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, van de Velde CJH, Rea D, Schnabel CA, Treuner K, Bayani J. Bartlett JMS, et al. Among authors: hasenburg a. Clin Cancer Res. 2024 Apr 15;30(8):1509-1517. doi: 10.1158/1078-0432.CCR-23-2436. Clin Cancer Res. 2024. PMID: 38345755 Free PMC article.
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D. Bartlett JM, et al. Among authors: hasenburg a. J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422407 Free PMC article. Clinical Trial.
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.
Bartlett JM, Bloom KJ, Piper T, Lawton TJ, van de Velde CJ, Ross DT, Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D. Bartlett JM, et al. Among authors: hasenburg a. J Clin Oncol. 2012 Dec 20;30(36):4477-84. doi: 10.1200/JCO.2012.42.8896. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045591 Clinical Trial.
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ. Fontein DB, et al. Among authors: hasenburg a. J Clin Oncol. 2013 Jun 20;31(18):2257-64. doi: 10.1200/JCO.2012.45.3068. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610112
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.
Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW. Bartlett JM, et al. Among authors: hasenburg a. Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3. Br J Cancer. 2013. PMID: 24091623 Free PMC article. Clinical Trial.
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.
Stephen J, Murray G, Cameron DA, Thomas J, Kunkler IH, Jack W, Kerr GR, Piper T, Brookes CL, Rea DW, van de Velde CJ, Hasenburg A, Markopoulos C, Dirix L, Seynaeve C, Bartlett JM. Stephen J, et al. Among authors: hasenburg a. Br J Cancer. 2014 Dec 9;111(12):2242-7. doi: 10.1038/bjc.2014.530. Epub 2014 Oct 14. Br J Cancer. 2014. PMID: 25314051 Free PMC article.
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Bartlett JM, et al. Among authors: hasenburg a. Arch Pathol Lab Med. 2016 Jan;140(1):66-74. doi: 10.5858/arpa.2014-0599-OA. Arch Pathol Lab Med. 2016. PMID: 26717057 Free article. Clinical Trial.
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Bayani J, Yao CQ, Quintayo MA, Yan F, Haider S, D'Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, Bartlett JMS. Bayani J, et al. Among authors: hasenburg a. NPJ Breast Cancer. 2017 Feb 15;3:3. doi: 10.1038/s41523-016-0003-5. eCollection 2017. NPJ Breast Cancer. 2017. PMID: 28649643 Free PMC article.
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Derks MGM, et al. Among authors: hasenburg a. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18. Lancet Oncol. 2017. PMID: 28732650 Clinical Trial.
Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ. Derks MGM, et al. Among authors: hasenburg a. Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6. Eur J Cancer. 2018. PMID: 29885375 Clinical Trial.
228 results